Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 1, 2012, Pages 37-42

  Chang, Kai Chih ^a   Lin, Ming Feng ^b,c   Lin, Nien Tsung ^a   Wu, Wen Jui ^a   Kuo, Han Yueh ^b,d   Lin, Teng Yi ^e   Yang, Tsai Lian ^e   Chen, Yu Chuan ^e   Liou, Ming Li ^f  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^f YUANPEI UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; Colistin; Rifampicin; Tigecycline

Indexed keywords

COLISTIN; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENTIATION; GENOTYPING TECHNIQUE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; TAIWAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CLUSTER ANALYSIS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ELECTROPHORESIS, GEL, PULSED-FIELD; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; PREVALENCE; RIFAMPIN; TAIWAN;

EID: 84856305826     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.019     Document Type: Article

References (29)

1. Fournier P.E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42:692-699.
2. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:3471-3484.
3. Bergogne-Bérézin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165.
4. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006, 12:826-836.
5. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005, 18:306-313.
6. Walther-Rasmussen J., Høiby N. OXA-type carbapenemases. JAntimicrob Chemother 2006, 57:373-383.
7. Tsakris A., Ikonomidis A., Poulou A., Spanakis N., Vrizas D., Diomidous M., et al. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. Clin Microbiol Infect 2008, 14:588-594.
8. Petersen P.J., Labthavikul P., Jones C.H., Bradford P.A. Invitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006, 57:573-576.
9. Motaouakkil S., Charra B., Hachimi A., Nejmi H., Benslama A., Elmdaghri N., et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006, 53:274-278.
10. Entenza J.M., Moreillon P. Tigecycline in combination with other antimicrobials: a review of invitro, animal and case report studies. Int J Antimicrob Agents 2009, 34:8. e1-9.
11. Navon-Venezia S., Leavitt A., Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. JAntimicrob Chemother 2007, 59:772-774.
12. Hernan R.C., Karina B., Gabriela G., Marcela N., Carlos V., Angela F. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microb Infect Dis 2009, 65:188-191.
13. Pantopoulou A., Giamarellos-Bourboulis E.J., Raftogannis M., Tsaganos T., Dontas I., Koutoukas P., et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007, 29:51-55.
14. Dizbay M., Tozlu D.K., Cirak M.Y., Isik Y., Ozdemir K., Arman D. Invitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 2010, 63:51-53.
15. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55:1619-1629.
16. Chen T.L., Siu L.K., Wu R.C., Shaio M.F., Huang L.Y., Fung C.P., et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007, 13:801-806.
17. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically 2009, Clinical and Laboratory Standards Institute, 8th informational supplement; M07-A8, CLSI, Wayne, PA.
18. Performance standards for antimicrobial susceptibility testing 2007, Clinical and Laboratory Standards Institute, 17th informational supplement; M100-S17, CLSO, Wayne, PA.
19. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxins B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190.
20. Hogg G.M., Barr J.G., Webb C.H. In-vitro activity of the combinations of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998, 41:494-495.
21. Seifert H., Dolzani L., Bressan R., van der Reijden T., van Strijen B., Stefanik D., et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005, 43:4328-4335.
22. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233-2239.
23. Liu J.W., Wang L.S., Cheng Y.J., Hsu G.J., Lu P.L., Liu Y.C., et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Int J Antimicrob Agents 2008, 32:188-191.
24. Lee Y.T., Huang L.Y., Chiang D.H., Chen C.P., Chen T.L., Wang F.D., et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009, 34:580-584.
25. Pachón-Ibáñez M.E., Docobo-Pérez F., López-Rojas R., Domínguez-Herrera J., Jiménez-Mejias M.E., García-Curiel A., et al. Efficacy of rifampicin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. JAntimicro Chemother 2006, 58:689-692.
26. Giamarellos-Bourboulis E.J., Xirouchaki E., Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001, 40:117-120.
27. Bassetti M., Repetto E., Righi E., Boni S., Diverio M., Molinari M.P., et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008, 61:417-420.
28. Jean S.S., Hsueh P.R., Lee W.S., Chang H.T., Chou M.Y., Chen I.S., et al. Nationwide surveillance of antimicrobial resistance among non-fermentative gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009, 33:266-271.
29. OxA-carrying imipenem-resistant Acinetobacter spp. in three hospitals in Taiwan. Diag Microb Infect Dis 2010, 66:195-199.